Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148342 · ClinicalTrials.gov registry record · Phase 1
Neurobiology and Pharmacokinets of Acute MDMA Administration
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
NCT01148342: Completed Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01148342 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 187 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01148342, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
Study Summary
Background: * 3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a synthetic psychoactive drug that has shown a steep increase in recreational use and abuse by young people in recent years. Research studies have reported that chronic MDMA users who also consume other legal and illegal substance show memory deficits; however, because of the combination of drugs often involved, it is difficult to determine MDMA s contribution to these effects. * Only a few studies have examined the immediate physical and behavioral effects of MDMA given at dose levels commonly used in young adults. Researchers are interested in using functional magnetic resonance imaging (fMRI) to examine changes in brain activity and function in MDMA users compared with users of other drugs and non-drug-using individuals. Objectives: \- To evaluate the effects of MDMA on thinking and brain function. Eligibility: \- Individuals between 18 and 30 years of age who are (1) current users of MDMA (2), current drug users who do not use MDMA, or (3) healthy non-drug-using volunteers. Design: * Participants will complete one training session and three scanning sessions. * Before the start of the study, participants will complete questionnaires about medical and psychological history, and provide information about past or current drug use. Researchers will introduce the tasks to be performed during the scanning session(s), and will allow participants to practice the tests. * Participants will provide urine, saliva, and hair samples for testing before the start of the study, and multiple times during each scanning session. * Participants who use MDMA and participants who use other drugs will stay overnight at the clinical center prior to each scanning session. Participants who do not use drugs can spend the night prior to scanning or arrive at the clinical center on the morning of the scanning session. * Participants who use MDMA will receive either MDMA or a placebo during the scann
Interventions
- DRUG MDMA
- DRUG (+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2004-02-10 |
| Est. Completion | 2012-07-18 |
| Phase | Phase 1 |
What the finished NCT01148342 record still lists
NCT01148342 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher).
The record links to 0 conditions, and to 2 interventions - of which MDMA is the first listed.
NCT01148342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01148342 about?
NCT01148342 is a clinical study titled "Neurobiology and Pharmacokinets of Acute MDMA Administration". Background: * 3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a synthetic psychoactive drug that has shown a steep increase in recreational use and abuse by young people in recent years. Research studies have reported that chronic MDMA users who also consume other legal and ...
What is the current status of trial NCT01148342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2004-02-10. Estimated completion is 2012-07-18.
What interventions are being tested in trial NCT01148342?
The interventions under investigation include: MDMA (DRUG), (+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules (DRUG).
Who is sponsoring clinical trial NCT01148342?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01148342's enrollment target sits among peer trials
187 290th of 2000 higher than 1,710 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI